Avalon GloboCare Announces Issuance of Patent for Novel CAR-T and CAR-NK Cell Technology in China

Core Insights - Avalon GloboCare Corp. has been granted a patent for its CAR-T and CAR-NK cell technology by the China National Intellectual Property Administration, marking a significant milestone in its global intellectual property strategy [1][2][3] Intellectual Property Expansion - The newly issued Chinese patent, co-developed with Arbele Limited, enhances Avalon's intellectual property portfolio and is already protected in the U.S. and other territories under the Patent Cooperation Treaty [2] - The patent covers technology aimed at improving the expansion, manufacturing, survival, and efficacy of CAR-T and CAR-NK cells, providing 20 years of protection from the issuance date [3] Commitment to Innovation - Avalon emphasizes its commitment to advancing immunotherapy technologies, as stated by CEO David Jin, highlighting the importance of this patent in strengthening the company's position in cell-based immunotherapy [3]